Company: RNAC
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001453687-25-000099
Chunk: 106

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 106
---
0 million on the accompanying consolidated balance sheets. The Company’s maximum exposure to loss related to this variable interest entity is limited to the carrying value of the investment. The Company has not provided financing to Cyrus other than the amount contractually required by the Series B Preferred Stock Purchase Agreement.

6. Net Income (Loss) Per Share Allocable to Common Stockholders

The Company used the treasury stock method to determine the number of dilutive shares for the three months ended June 30, 2025 and 2024. The following table sets forth the computation of basic and diluted net income (loss) per share allocable to 

13

common stockholders for the three and six months ended June 30, 2025 and 2024 (in thousands, except share and per-share data): Three Months EndedJune 30,Six Months EndedJune 30, 2025202420252024Numerator:     Net income (loss)$15,886 $13,836 $(1,824)$(42,988)     Less: Undistributed earnings allocable to participating securities(2,628)(4,208)— —      Net income (loss) allocable to shares of common stock - basic and diluted$13,258 $9,628 $(1,824)$(42,988)Denominator:     Weighted-average common shares outstanding - basic25,980,262 16,723,479 25,941,670 11,068,749      Dilutive effect of employee equity incentive plans466,989 1,067,664 — —      Weighted-average common shares outstanding - diluted26,447,251 17,791,143 25,941,670 11,068,749 Net income (loss) per share:     Basic$0.51 $0.58 $(0.07)$(3.88)     Diluted$0.50 $0.54 $(0.07)$(3.88)The following table represents the potential dilutive shares of common stock excluded from the computation of the diluted net income (loss) per share allocable to common stockholders for all periods presented, as the effect would have been anti-dilutive:  Three Months EndedJune 30,Six Months EndedJune 30, 2025202420252024Common stock options and restricted stock units2,336,681 740,211